Literature DB >> 12109872

Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Jesús Avila1, Filip Lim, Francisco Moreno, Carlos Belmonte, A Claudio Cuello.   

Abstract

Alzheimer's disease (AD) is the most usual neurodegenerative disorder leading to dementia in the aged human population. It is characterized by the presence of two main brain pathological hallmarks: senile plaques and neurofibrillary tangles (NFTs). NFTs are composed of fibrillar polymers of the abnormally phosphorylated cytoskeletal protein tau.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12109872     DOI： 10.1385/MN:25:3:213

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN： 0893-7648            Impact factor:   5.590


  181 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Microtubule-associated protein tau is phosphorylated by protein kinase C on its tubulin binding domain.

Authors:  I Correas; J Díaz-Nido; J Avila
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules.

Authors:  M Pérez; F Lim; M Arrasate; J Avila
Journal:  J Neurochem       Date:  2000-06       Impact factor: 5.372

Review 5.  Tau protein pathology in neurodegenerative diseases.

Authors:  M G Spillantini; M Goedert
Journal:  Trends Neurosci       Date:  1998-10       Impact factor: 13.837

6.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.

Authors:  P J Lu; G Wulf; X Z Zhou; P Davies; K P Lu
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

7.  In vitro conditions for the self-polymerization of the microtubule-associated protein, tau factor.

Authors:  E Montejo de Garcini; J Avila
Journal:  J Biochem       Date:  1987-12       Impact factor: 3.387

8.  Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells.

Authors:  E Sadot; D Gurwitz; J Barg; L Behar; I Ginzburg; A Fisher
Journal:  J Neurochem       Date:  1996-02       Impact factor: 5.372

9.  Analysis of microtubule-associated protein tau glycation in paired helical filaments.

Authors:  M D Ledesma; P Bonay; C Colaço; J Avila
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

10.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173
View more
  11 in total

1.  RNA helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5' splice site.

Authors:  Amar Kar; Kazuo Fushimi; Xiaohong Zhou; Payal Ray; Chen Shi; Xiaoping Chen; Zhiren Liu; She Chen; Jane Y Wu
Journal:  Mol Cell Biol       Date:  2011-02-22       Impact factor: 4.272

2.  Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice.

Authors:  I Ferrer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 3.  Cognition, language, and clinical pathological features of non-Alzheimer's dementias: an overview.

Authors:  Jamie Reilly; Amy D Rodriguez; Martine Lamy; Jean Neils-Strunjas
Journal:  J Commun Disord       Date:  2010-05-06       Impact factor: 2.288

4.  Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies.

Authors:  Teresa Rodriguez-Martin; Mariano A Garcia-Blanco; S Gary Mansfield; Andrew C Grover; Michael Hutton; Qingming Yu; Jianhua Zhou; Brian H Anderton; Jean-Marc Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

5.  Amyloid-beta peptide binds to microtubule-associated protein 1B (MAP1B).

Authors:  Goar Gevorkian; Alfonso Gonzalez-Noriega; Gonzalo Acero; Jorge Ordoñez; Colette Michalak; Maria Elena Munguia; Tzipe Govezensky; David H Cribbs; Karen Manoutcharian
Journal:  Neurochem Int       Date:  2007-11-12       Impact factor: 3.921

6.  Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.

Authors:  Karelle Leroy; Alexis Bretteville; Katharina Schindowski; Emmanuel Gilissen; Michèle Authelet; Robert De Decker; Zehra Yilmaz; Luc Buée; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2007-08-09       Impact factor: 4.307

Review 7.  Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.

Authors:  Makoto Hashimoto; Edward Rockenstein; Leslie Crews; Eliezer Masliah
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 8.  Intracellular A-beta amyloid, a sign for worse things to come?

Authors:  Valentina Echeverria; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

9.  Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice.

Authors:  Yao Zhang; Rong-Hong Ma; Xia-Chun Li; Jia-Yu Zhang; Hai-Rong Shi; Wei Wei; Dan-Ju Luo; Qun Wang; Jian-Zhi Wang; Gong-Ping Liu
Journal:  Front Aging Neurosci       Date:  2014-06-17       Impact factor: 5.750

10.  S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model.

Authors:  Hee Jin Kim; Keun-A Chang; Tae-Young Ha; Jeonga Kim; Sungji Ha; Ki-Young Shin; Cheil Moon; Wolfgang Nacken; Hye-Sun Kim; Yoo-Hun Suh
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.